Table 2 Baseline patient clinical characteristics
Cases | Controls | |
|---|---|---|
N | 387 | 109 |
Sex | ||
Female | 193 (49.9%) | 53 (48.6%) |
Male | 194 (50.1%) | 56 (51.4%) |
Age, year median (range) | 59.7 (22.25–81.08) | 56.3 (17.49–88.3) |
BMI, kg m−2 median (range) | 25.93 (15–43) | 27.33 (15–40) |
Performance status | ||
0 | 106 (27.4%) | 25 (22.9%) |
1 | 277 (71.6%) | 82 (75.3%) |
2 | 4 (1.0%) | 2 (1.8%) |
Number of previous lines of chemotherapy | 2 (0–11) | 2 (0–11) |
Tumour type | ||
Lung and mesothelioma | 48 (12.4%) | 11 (10.1%) |
Colorectal | 99 (25.6%) | 16 (14.7%) |
Gynaecological (ovarian, cervical, endometrial) | 59 (15.2%) | 6 (5.5%) |
Breast | 33 (8.5%) | 15 (13.8%) |
Prostate | 22 (5.7%) | 10 (9.2%) |
RCC | 17 (4.4%) | 3 (2.8%) |
Others | 109 (28.2%) | 48 (44.0%) |
RMH score a | ||
0 | 85 (22.0%) | 25 (22.9%) |
1 | 129 (33.3%) | 32 (29.4%) |
2 | 107 (27.6%) | 32 (29.4%) |
3 | 52 (13.5%) | 20 (18.3%) |
Unknown | 14 (3.6%) | – |
Time on trial (days) | 94.61 (1–1524) | 124,75 (1–1096) |
